Table 2.

Summary-of-findings table

		Effect estimate
Outcome	Certainty of evidence	RR (95% CI)	Absolute change, per 1000
Ticagrelor vs prasugrel
MACE	Low∗†	1.23 (1.01–1.49)	15 more (from 1 to 31 more)
Death	Moderate∗	1.12 (0.86–1.46)	—
Stent thrombosis	Low‡	1.21 (0.74–1.98)	—
Major bleed	Moderate†	1.01 (0.78–.132)	—
De-escalation to clopidogrel vs potent P2Y12 inhibitor
MACE	Moderate∗	0.76 (0.55–1.06)	—
Death	Low‡	0.75 (0.21–2.69)	—
Stent thrombosis	Low‡	1.17 (0.39–3.47)	—
Major bleed	High	0.51 (0.28–0.92)	9 fewer (from 2 to 14 fewer)
De-escalation of prasugrel dose to 5 mg daily vs continuation of prasugrel 10 mg daily
MACE	Low‡	0.76 (0.40–1.45)	—
Death	Low‡	0.71 (0.32–1.60)	—
Stent thrombosis	Low‡	0.33 (0.03–3.19)	—
Major bleed	Low‡	1.12 (0.43–2.90)	—

CI, confidence interval, MACE, major adverse cardiac events; P2Y₁₂, purinergic receptor type Y, subtype 12; RR, risk ratio.

^∗Rated down 1 category for serious imprecision.

^†Rated down 1 category for serious inconsistency.

^‡Rated down 2 categories for very serious imprecision.